13649cf2-1dc4-408f-9063-31a2b9bb7157
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 69
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.490
- E2F_TARGETS+0.480
- MITOTIC_SPINDLE+0.380
- PI3K_AKT_MTOR_SIGNALING+0.350
- MTORC1_SIGNALING+0.290
- PROTEIN_SECRETION+0.280
- ANDROGEN_RESPONSE+0.240
- CHOLESTEROL_HOMEOSTASIS+0.230
- UNFOLDED_PROTEIN_RESPONSE+0.230
- SPERMATOGENESIS+0.220
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.550
- INTERFERON_GAMMA_RESPONSE-0.480
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.450
- ALLOGRAFT_REJECTION-0.440
- ANGIOGENESIS-0.420
- INFLAMMATORY_RESPONSE-0.330
- IL6_JAK_STAT3_SIGNALING-0.320
- COAGULATION-0.310
- COMPLEMENT-0.270
- KRAS_SIGNALING_UP-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SAMN03290953 | — | — | 0.910 |
| 2 | TCGA-22-4591-01A-01R-1201-07 | — | cohortSQ1 | 0.889 |
| 3 | SAMN03290941 | — | — | 0.882 |
| 4 | TCGA-B6-A0WV-01A-11R-A109-07 | — | B | 0.879 |
| 5 | SAMN03290933 | — | — | 0.874 |
| 6 | TCGA-HQ-A2OF-01A-11R-A26T-07 | — | — | 0.874 |
| 7 | R360 | — | — | 0.873 |
| 8 | TCGA-33-A4WN-01A-11R-A262-07 | — | cohortSQ2 | 0.872 |
| 9 | 5d396a37-9b3d-4255-a3bd-f4a7c9480aee | — | — | 0.870 |
| 10 | TCGA-HQ-A2OE-01A-11R-A206-07 | — | — | 0.867 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.490 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.480 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.380 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.350 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.290 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.280 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.240 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.230 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.230 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.220 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.110 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.090 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.080 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.050 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.050 | Idelalisib | — uncovered |